Document Detail

Color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy.
MedLine Citation:
PMID:  10811079     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate color vision in epilepsy patients treated with vigabatrin or carbamazepine monotherapy and to evaluate the association between vigabatrin-induced visual field defects and dyschromatopsia. DESIGN: Nonrandomized comparative trial. PARTICIPANTS: Thirty-two epilepsy patients treated with vigabatrin monotherapy, 18 patients treated with carbamazepine monotherapy, and 47 age-matched healthy controls were examined. MAIN OUTCOME MEASURES: Color vision was examined with Standard Pseudoisochromatic Plates 2 (SPP2) screening test, Farnsworth-Munsell 100 (FM 100) hue test, and Color Vision Meter 712 anomaloscope. RESULTS: Abnormal color perception was found in 32% of the epilepsy patients treated with vigabatrin monotherapy and 28% of the epilepsy patients treated with carbamazepine monotherapy. The total error score in the Farnsworth-Munsell 100 hue test was abnormally high in the vigabatrin monotherapy patients who had concentrically constricted visual fields and a statistically significant correlation was found between the temporal visual field extents and the age-adjusted Farnsworth-Munsell 100 total error score in vigabatrin monotherapy patients (R = .533, P = 0.003 in the right eye, R = .563, P = 0.001 in the left eye). Four of 31 (12%) vigabatrin monotherapy patients, and 1 of 18 (6%) carbamazepine monotherapy patients had a blue axis in Farnsworth-Munsell 100 hue test. In the anomaloscope, there were a few pathologic findings in both groups. In the SPP2 screening test, a few plates were not seen in both groups. CONCLUSIONS: Both examined antiepileptic drugs, vigabatrin and carbamazepine, cause acquired color vision defects. The abnormal color perception seems to be associated with constricted visual fields in the vigabatrin monotherapy patients. The duration of carbamazepine therapy correlates with high FM100 total error score. The best method for detecting dyschromatopsia in patients treated with vigabatrin or carbamazepine was the Farnsworth-Munsell 100 hue test. The SPP2 screening test does not seem to be useful in clinical practice.
I Nousiainen; R Kälviäinen; M Mäntyjärvi
Related Documents :
10565519 - Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration.
10582809 - Evaluation of transmyocardial laser revascularization (tmlr) by gated myocardial perfus...
18569799 - An unusual case of central serous chorioretinopathy in a patient with acute retinal nec...
9009359 - Keratoplasty à chaud in severe keratitis.
10719859 - Visual loss after spine surgery: a survey.
15920569 - Assessment of visual function in chronic progressive external ophthalmoplegia.
19899329 - Cyp2c9 gene analysis of some iranian hypersensitive patients to warfarin.
21567189 - Double-contrast barium enteroclysis as a patency tool for nonsteroidal anti-inflammator...
4064589 - Opera-glass deformity and tendon rupture in a patient with systemic lupus erythematosus.
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Ophthalmology     Volume:  107     ISSN:  0161-6420     ISO Abbreviation:  Ophthalmology     Publication Date:  2000 May 
Date Detail:
Created Date:  2000-05-18     Completed Date:  2000-05-18     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  884-8     Citation Subset:  IM    
Department of Ophthalmology, Kuopio University Hospital, Finland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticonvulsants / adverse effects*,  therapeutic use
Carbamazepine / adverse effects*,  therapeutic use
Color Perception / drug effects*,  physiology
Color Perception Tests
Color Vision Defects / chemically induced*,  physiopathology
Epilepsy / drug therapy*,  physiopathology
Middle Aged
Vigabatrin / adverse effects*,  therapeutic use
Visual Fields / drug effects
Reg. No./Substance:
0/Anticonvulsants; 298-46-4/Carbamazepine; 60643-86-9/Vigabatrin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Highly active antiretroviral therapy-related immune recovery in AIDS patients with cytomegalovirus r...
Next Document:  Rand-Stein analgesia protocol for cataract surgery.